6-methoxy-5-methyl-N-[(1-methyl-1H-pyrazol-4-yl)methyl]-2-{[2-(1,5-naphthyridin-2-yl)cyclopropyl]methoxy}pyrimidin-4-amine | 1370510-26-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: 6-methoxy-5-methyl-N-[(1-methyl-1H-pyrazol-4-yl)methyl]-2-{[2-(1,5-naphthyridin-2-yl)cyclopropyl]methoxy}pyrimidin-4-amine
• 英文别名: 6-methoxy-5-methyl-N-[(1-methylpyrazol-4-yl)methyl]-2-[[(1S,2S)-2-(1,5-naphthyridin-2-yl)cyclopropyl]methoxy]pyrimidin-4-amine
• CAS: 1370510-26-1
• 化学式: C₂₃H₂₅N₇O₂
• 分子量: 431.497
• InChiKey: DTVOGHZNBWTEJY-SJORKVTESA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  32
• 可旋转键数：
  8
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.35
• 拓扑面积：
  99.9
• 氢给体数：
  1
• 氢受体数：
  8

反应信息

• 作为产物：
  描述：

  6-chloro-5-methyl-N-[(1-methyl-1H-pyrazol-4-yl)methyl]-2-{[(1S,2S)-2-(1,5-naphthyridin-2-yl)cyclopropyl]methoxy}pyrimidin-4-amine 、 sodium methylate 以 甲醇 为溶剂， 以50%的产率得到6-methoxy-5-methyl-N-[(1-methyl-1H-pyrazol-4-yl)methyl]-2-{[2-(1,5-naphthyridin-2-yl)cyclopropyl]methoxy}pyrimidin-4-amine
  参考文献：
  名称：

  2-ALKOXY PYRIMIDINE PDE10 INHIBITORS

  摘要：

  公开号：

  EP2621276B1

文献信息

• ALKOXY PYRIMIDINE PDE10 INHIBITORS
  申请人：Cox Christopher D.

  公开号：US20130158056A1

  公开（公告）日：2013-06-20

  The present invention is directed to 2-alkoxy pyrimidine compounds which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 10 (PDE10). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis or Huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction.

  本发明涉及2-烷氧基嘧啶化合物，其可用作治疗与磷酸二酯酶10（PDE10）相关的中枢神经系统疾病的治疗剂。本发明还涉及使用这些化合物治疗神经系统和精神疾病，如精神分裂症、精神病或亨廷顿病，以及与纹状体低功能或基底节功能障碍相关的疾病。
• US8785467B2
  申请人：——

  公开号：US8785467B2

  公开（公告）日：2014-07-22
• [EN] 2-ALKOXY PYRIMIDINE PDE10 INHIBITORS<br/>[FR] INHIBITEURS DE 2-ALCOXY PYRIMIDINE PDE10
  申请人：MERCK SHARP & DOHME

  公开号：WO2012044561A2

  公开（公告）日：2012-04-05

  The present invention is directed to 2-alkoxy pyrimidine compounds which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 10 (PDE10). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis or Huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction.